相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity
Christopher Ronald Funk et al.
BLOOD (2022)
CD38 knocKout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
Mark Gurney et al.
HAEMATOLOGICA (2022)
IL-6/IFN-gamma double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
Huihui Zhang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)
CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
Qingya Cui et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells
Connor J. Dwyer et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Recent advances in CAR-T cell engineering
Ruihao Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
Sophia Stock et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Mohit Sachdeva et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
Jianshu Wei et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia
Bola S. Hanna et al.
LEUKEMIA (2019)
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML
Sun Yao et al.
FRONTIERS IN ONCOLOGY (2019)
PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
Wenting Zheng et al.
LEUKEMIA (2018)
Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells
Na An et al.
MOLECULAR PHARMACEUTICS (2018)
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites
Aleksei Titov et al.
CELL DEATH & DISEASE (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Enhanced Therapeutic Efficacy and Memory of Tumor-Specific CD8 T Cells by Ex Vivo PI3K-δ Inhibition
Rasha Abu Eid et al.
CANCER RESEARCH (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Dose-Dependent Suppression of Cytokine production from T cells by a Novel Phosphoinositide 3-Kinase Delta Inhibitor
Emily E. Way et al.
SCIENTIFIC REPORTS (2016)
Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Esther Drent et al.
HAEMATOLOGICA (2016)
CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
S. S. Kenderian et al.
LEUKEMIA (2015)
Treatment of CD33-directed Chimeric Antigen Receptor-modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia
Quan-shun Wang et al.
MOLECULAR THERAPY (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
PI3Kδ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes
Eva Maria Putz et al.
PLOS ONE (2012)
PI3K p110δ regulates T-cell cytokine production during primary and secondary immune responses in mice and humans
Dalya R. Soond et al.
BLOOD (2010)
分享论文
